Nisa Investment Advisors LLC Sells 2,600 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Nisa Investment Advisors LLC lessened its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 1.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 203,838 shares of the company’s stock after selling 2,600 shares during the period. Nisa Investment Advisors LLC’s holdings in Elanco Animal Health were worth $2,468,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Mitchell & Pahl Private Wealth LLC raised its position in shares of Elanco Animal Health by 12.6% in the fourth quarter. Mitchell & Pahl Private Wealth LLC now owns 43,728 shares of the company’s stock worth $530,000 after buying an additional 4,881 shares in the last quarter. 180 Wealth Advisors LLC raised its position in Elanco Animal Health by 10.4% during the fourth quarter. 180 Wealth Advisors LLC now owns 26,732 shares of the company’s stock valued at $324,000 after purchasing an additional 2,525 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in Elanco Animal Health by 24.0% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after purchasing an additional 209,734 shares in the last quarter. Everence Capital Management Inc. purchased a new stake in Elanco Animal Health during the fourth quarter valued at about $209,000. Finally, JPMorgan Chase & Co. raised its position in Elanco Animal Health by 76.6% during the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock valued at $147,747,000 after purchasing an additional 4,361,799 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on ELAN shares. Leerink Partners started coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Stifel Nicolaus cut their price objective on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. UBS Group assumed coverage on Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective on the stock. Barclays raised their target price on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Finally, Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $16.43.

Elanco Animal Health Trading Up 0.2 %

Shares of Elanco Animal Health stock opened at $12.09 on Monday. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The firm has a market cap of $5.97 billion, a price-to-earnings ratio of 30.21, a PEG ratio of 2.57 and a beta of 1.41. Elanco Animal Health Incorporated has a twelve month low of $11.11 and a twelve month high of $18.80. The business has a 50-day moving average price of $12.31 and a 200-day moving average price of $13.28.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the firm posted $0.18 earnings per share. The company’s revenue was down 3.6% on a year-over-year basis. Equities research analysts anticipate that Elanco Animal Health Incorporated will post 0.92 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.